Fig. 3

Systemic STING agonist activates CD8⁺ T cells and induces tumor regression in mice with pancreatic cancer. a Orthotopic tumor implantation and treatment strategy. b Excised tumor wet weights from experimental and control mice. Values are mean ± SD, n = 8 mice per group. *, P ≤ 0.05. c-e Tumors were collected and processed into single cell suspensions and immune profiling of infiltrated lymphocytes in DMXAA-treated and control mice completed using flow cytometry. c The percentage of CD8⁺ T cells as a percent of tumor infiltrated CD45⁺ cells. d CD4:CD8 ratio of CD45⁺ gated leukocytes. f Percentage of Foxp3⁺ T cells as a percent of CD4⁺ T cells. f Percentage of infiltrating CD8⁺ T cells expressing Ki-67 and Granzyme B (GB) within the tumor. g Spleen CD8⁺ T cells were isolated by immunomagnetic sorting and tested in IFN-γ ELISPOT assays using KPC1242 tumor cells as stimulators. Graphs represent the mean spot forming units (SFU) ± SD of 2 independent experiments. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001